Updates

ICYMI: The Atlantic – Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

Mar 30, 2019

Just how expensive do prescription drugs need to be to fund innovative Read More

They Said It! Lawmakers Advance Key Drug Pricing Bills

Mar 28, 2019

House Energy & Commerce Members Recommit To Bipartisan Action As Critical Read More

CSRxP Applauds House Lawmakers For Keeping Momentum Going On Key Drug Price Legislation

Mar 27, 2019

U.S. House Committee On Energy & Commerce Health Subcommittee Will Markup Read More

ICYMI: Drug Prices Are A Matter Of Life And Death

Mar 21, 2019

The Hill Lauren Aronson March 21, 2019 https://thehill.com/blogs/congress-blog/4 Read More

ICYMI: Lack Of Competition In Drug Market Drives Up Medicare & Medicaid Spending

Mar 18, 2019

In case you missed it, the Centers for Medicare and Medicaid Services (CMS) Read More

Good Medicine: Congress Should Pass Market-Based Solutions to Spur Prescription Drug Competition

Mar 13, 2019

The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act Read More

CSRxP: Legislative Hearing on Drug Pricing Bills a Positive First Step, Now More Action Needed

Mar 13, 2019

Today, members of the U.S. House Committee on Energy & Commerce Read More

Second Opinion: Rebate Rule Will Hike Premiums On Seniors

Mar 12, 2019

Lowering prescription drug prices is a laudable focus of the Trump Read More

Questioning The Rebate Rule

Mar 12, 2019

Secretary Azar Recently Noted The Effectiveness Of PBMs Now Targeted By Agency Read More

Trump Administration Should Focus on Market-Based Solutions to Alleviate Drug Prices

Mar 11, 2019

As Secretary Azar Heads To Capitol Hill, CSRxP Encourages Lawmakers To Read More

Headlines: Lawmakers, Patients, Experts Keep-Up Drumbeat For Action On Drug Prices

Mar 9, 2019

Three More Congressional Hearings Tackle Big Pharma’s Anti-Competitive Read More

ICYMI: House Judiciary Subcommittee on Anti-Trust Members Tout Benefits of CREATES Act

Mar 8, 2019

During today’s House Judiciary Subcommittee on Anti-trust hearing on Read More